Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-08-03NRIX144CHRISTINE RING plan to sell securities of NURIX THERAPEUTICS INC under Form 144MEDIUM
CHRISTINE RING filed Form 144 to notify SEC of plan to sell 16589 units of NURIX THERAPEUTICS INC securities around 2026-08-03, with aggregate market value of $385,030.69. The total outstanding units is 103781683.0. The amount planned to be sold represents 0.02% of total outstanding units; Recent transactions in past 3...
Mid CapBiotechnology
2026-08-03OBIO144Sherman Darren plan to sell securities of Orchestra BioMed Holdings, Inc. under Form 144MEDIUM
Sherman Darren filed Form 144 to notify SEC of plan to sell 15000 units of Orchestra BioMed Holdings, Inc. securities around 2026-08-03, with aggregate market value of $61,291.68. The total outstanding units is 59880715.0. The amount planned to be sold represents 0.03% of total outstanding units; Recent transactions in...
Micro CapBiotechnology
2026-08-03CAI144GEORGE H POSTE plan to sell securities of CARIS LIFE SCIENCES, INC. under Form 144MEDIUM
GEORGE H POSTE filed Form 144 to notify SEC of plan to sell 20000 units of CARIS LIFE SCIENCES, INC. securities around 2026-08-03, with aggregate market value of $325,000.00. The total outstanding units is 282680695.0. The amount planned to be sold represents 0.01% of total outstanding units; ...
Mid CapBiotechnology
2026-08-03PGEN144Shah Rutul R plan to sell securities of PRECIGEN, INC. under Form 144MEDIUM
Shah Rutul R filed Form 144 to notify SEC of plan to sell 33772 units of PRECIGEN, INC. securities around 2026-08-03, with aggregate market value of $219,518.00. The total outstanding units is 356510980.0. The amount planned to be sold represents 0.01% of total outstanding units; Recent transactions in past 3 months in...
Mid CapBiotechnology